Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 2/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503296 | 0.77 | ALDH1A1 (0.38) | CASP6NSD2HSP90AA1HSP90AB1KMT2A | |
| SCHEMBL17796068 | 0.77 | NSD2 (0.36) | CASP6NSD2HSP90AA1KMT2AMEN1 | |
| SCHEMBL31703523 | 0.74 | OPRL1 (0.38) | HSP90AA1HSP90AB1KMT2ANOS3NOS1 | |
| SCHEMBL23362965 | 0.74 | OPRL1 (0.38) | HSP90AA1HSP90AB1KMT2ANOS3NOS1 | |
| SCHEMBL16704264 | 0.73 | NSD2 (0.40) | CASP6NSD2 | |
| SCHEMBL6983787 | 0.73 | NSD2 (0.34) | CASP6NSD2ALDH1A1 | |
| SCHEMBL21505363 | 0.73 | TRIM24 (0.46) | CASP6NSD2HSP90AA1KMT2AMEN1 | |
| SCHEMBL27816652 | 0.72 | DRD2 (0.42) | — | |
| SCHEMBL27841433 | 0.71 | SLC6A2 (0.50) | CASP6NSD2 | |
| SCHEMBL28167655 | 0.71 | OPRL1 (0.36) | HSP90AA1HSP90AB1KMT2ANOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633313-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633313-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633313-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2513109-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011075628-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075628-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-5721259-A | Method of using 2-formylpyridine thiosemicarbazone compounds | YALE UNIVERSITY (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0570294-B1 | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | UNIV YALE (US) | 1997-07-30 | — | — | EP | disclosed |
| US-5281715-A | 2-formylpyridine thiosemicarbazone compounds | YALE UNIVERSITY (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0570294-A1 | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | YALE UNIVERSITY (US) | 1993-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | CASP6 3391/4885NSD2 158/4885HSP90AA1 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.